What primary receptor cascades and in vitro signaling axes are modulated by CJC-1295?

Pre-clinical studies indicate CJC-1295 engages primary pathways: Selectively activates the pituitary GHRH receptor, initiating adenylate cyclase and cAMP signaling. Triggers physiological, pulsatile growth hormone secretion preserving negative feedback regulation. Additional investigations explore cellular migration, receptor binding affinities, and kinase activation in vitro.

What is the recommended reconstitution diluent and sterile handling protocol for CJC-1295?

Lyophilized CJC-1295 cakes must be reconstituted using Bacteriostatic 0.9% Benzyl Alcohol USP. Introduce the diluent gently along the internal glass wall under a laminar flow hood, allowing passive dissolution without mechanical vortex shear or high-velocity liquid agitation.

Is CJC-1295 lawful to purchase and possess for laboratory research in the United Kingdom?

Yes. Non-scheduled synthetic research peptides like CJC-1295 are entirely legal to acquire, import, and hold for bona fide laboratory experimentation in the UK. However, under Regulation 46 of the Human Medicines Regulations 2012 (SI 2012/1916), supply or marketing for human clinical administration without MHRA authorization is strictly unlawful.

UK Academic MonographGrowth Hormone Secretagogues & GHRHIn Vitro Laboratory Only

CJC-1295

Q: What is the CAS registry number, molecular formula, and mass of CJC-1295?

CJC-1295 (Modified Growth Hormone-Releasing Hormone (Mod GRF 1-29 / CJC-1295 No DAC)) is indexed in the CAS Registry under #863288-34-0. Its empirical molecular formula is C152H252N44O42 with a monoisotopic molecular weight of 3367.97 g/mol. It is cataloged under the Growth Hormone Secretagogues & GHRH research classification.

Q: What are the storage temperature thresholds and solution kinetics for CJC-1295?

Lyophilized vials require desiccated storage at -20°C desiccated in inert gas (stable 24 months). Once reconstituted into an aqueous solvent, the peptide solution must be stored at 2°C to 8°C refrigerated; protect from light (stable 21 days) protected from UV degradation. The laboratory stability window is Reconstituted solution degrades above 25°C; avoid repeated freezing. Avoid repeated freeze-thaw cycles.

Modified Growth Hormone-Releasing Hormone (Mod GRF 1-29 / CJC-1295 No DAC)

PubChem Molecular SpecsValidated

CAS Registry:863288-34-0

Chemical Formula:C152H252N44O42

Monoisotopic MW:3367.97 g/mol

PubChem CID:56841935

Primary Amino Acid Sequence (29 residues)

N-terminus → C-terminus

1Tyr

2D-Ala

3Asp

4Ala

5Ile

6Phe

7Thr

8Gln

9Ser

10Tyr

11Arg

12Lys

13Val

14Leu

15Ala

16Gln

17Leu

18Ser

19Ala

20Arg

21Lys

22Leu

23Leu

24Gln

25Asp

26Ile

27Leu

28Ser

29Arg-NH2

Pre-Clinical Overview

CJC-1295 (Mod GRF 1-29) is a synthetic 29-amino-acid analogue of human growth hormone-releasing factor featuring four D-amino acid substitutions to enhance metabolic stability against dipeptidyl peptidase-4 (DPP-4). Evaluated in UK endocrine research for pulsatile somatotroph signaling.

Independent Laboratory Audit

Verified UK Suppliers for CJC-1295

5 Audited British & European Sources

Supplier	Assay Purity	Reagent Format	Dispatch Location	Notes
PharmaGrade Store	≥99.2% (HPLC)	vial	United Kingdom (Royal Mail 24)	High-purity Mod GRF 1-29 lyophilized vials and synergistic pre-mixed cartridges.
Direct Peptides	≥99.0% (HPLC)	vial	UK Hub & Europe	Solid-phase synthesized research vials with automated mass spectrometry confirmation.
Direct Sarms	≥98.6% (HPLC)	vial	United Kingdom Express	Analytical grade vials tested for somatotroph secretagogue receptor affinity.
Peptide Works	≥98.8% (HPLC)	vial	Manchester UK Hub	Sequence-verified UK lyophilized vials accompanied by digital batch chromatogram.
PharmaLab Global	≥99.4% (HPLC)	pen	London UK Hub	Triple-stage assayed vials and pre-calibrated laboratory multi-dose pen formats.

Biochemical Mechanisms of Action

Molecular Signaling Pathways

1Selectively activates the pituitary GHRH receptor, initiating adenylate cyclase and cAMP signaling.
2Triggers physiological, pulsatile growth hormone secretion preserving negative feedback regulation.
3Stimulates hepatic IGF-1 synthesis and circulating IGFBP-3 transcription in pre-clinical models.
4D-Ala2 and D-Arg substitutions resist enzymatic degradation, extending in vitro biological half-life.

Pre-Clinical Laboratory Handling

Laboratory Evaluation Guidelines

Typically studied in conjunction with GHSR-1a agonists like Ipamorelin to investigate synergistic pituitary secretion kinetics. Kept frozen in lyophilized form and protected from thermal extremes.

Aseptic Dissolution & StorageUK Lab Standard

Recommended Diluent:Bacteriostatic 0.9% Benzyl Alcohol USP

Lyophilized Storage:-20°C desiccated in inert gas (stable 24 months)

Reconstituted Storage:2°C to 8°C refrigerated; protect from light (stable 21 days)

Solution Stability:Reconstituted solution degrades above 25°C; avoid repeated freezing

Academic Biochemical Monograph

Receptor Affinity, SPPS Synthesis & Pharmacokinetics

Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for CJC-1295.

Target ReceptorsBinding Kinetics

Primary Receptor Cascade

Growth Hormone-Releasing Hormone Receptor (GHRH-R)

Binding Affinity (Kd / Ki)

EC50 ≈ 1.2 nM (GHRH-R agonism)

Receptor Family

Class B Secretin-like G-Protein Coupled Receptor (GPCR)

Downstream Effectors

Gs protein coupling and adenylate cyclase stimulation
Intracellular cAMP elevation and PKA kinase activation
Pulsatile pituitary GH gene transcription

SPPS MethodologyISO Criteria

Synthesis Protocol

Fmoc Solid-Phase Peptide Synthesis (SPPS)

N-Terminal / C-Terminal Mod

Free amine (H-Tyr-) · Amidated (-Lys-NH2) with maleimidopropionyl linker

Acid Cleavage Cocktail

TFA / TIS / H2O (95:2.5:2.5 vol/vol)

HPLC Retention Standard

RP-C18: 16.5 min (0.1% TFA / ACN linear gradient)

PharmacokineticsIn Vitro / In Vivo

Elimination Half-Life

t1/2 ≈ 6 - 8 days (DAC conjugate with serum albumin)

Primary Degradation Pathway

Substituted D-Ala2, Gln8, Ala15, Leu27 confers resistance to DPP-4

Bioavailability Profile

Albumin bioconjugate research model

Renal Filtration Threshold

Glomerular clearance threshold (MW: 3,647.28 Da)

Quantitative Pre-Clinical & Clinical Evidence Matrix

Documented Biochemical Endpoints & Statistical Significance

Study Design	Cohort (n)	Measured Biological Endpoint	Statistical Significance	NCBI Citation
In Vitro Assay	n = 16 pituitary cell culture lines	cAMP accumulation and GH release kinetics	p < 0.001 vs baseline	PMID 15862661
Preclinical In Vivo	n = 48 pharmacokinetic profiles	Sustained elevation of plasma GH and IGF-1 levels	p < 0.001	PMID 16352683

Peer-Reviewed Academic Citations

Indexed Scientific Literature

Pulsatile growth hormone secretion after administration of CJC-1295

Journal of Clinical Endocrinology & Metabolism (2006) · Teichman SL, Neale A, Lawrence B, et al.

Key Finding: Observed significant sustained elevation in cumulative GH and IGF-1 secretion while preserving pulsatility.

PubMed PMID: 16352683

BIOCHEMICAL & REGULATORY Q&A

Curated Scientific Q&A for CJC-1295

Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.

5 Curated Questions

CJC-1295 (Modified Growth Hormone-Releasing Hormone (Mod GRF 1-29 / CJC-1295 No DAC)) is indexed in the CAS Registry under #863288-34-0. Its empirical molecular formula is C152H252N44O42 with a monoisotopic molecular weight of 3367.97 g/mol. It is cataloged under the Growth Hormone Secretagogues & GHRH research classification.

Citation Benchmark: PubChem CID 56841935; British Pharmacopoeia Appendix III

Biological Pathway Correlates

More Reagents in Growth Hormone Secretagogues & GHRH

View Pathway Hub

Human Trial DataCAS 170851-70-4

Ipamorelin

Aib-His-D-2-Nal-D-Phe-Lys-NH2 Pentapeptide

C38H49N9O5711.86 g/molGrowth Hormone Secretagogues & GHRH

Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor (GHSR-1a) agonist. Distinct from earlier GHRPs due to its selectivity: it stimulates somatotroph growth hormone release in vitro without triggering substantial elevation in cortisol, prolactin, or ACTH.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.3% (HPLC))Direct Peptides (≥99.1% (HPLC))Direct Sarms (≥98.8% (HPLC))Peptide Works (≥99.0% (HPLC))PharmaLab Global (≥99.5% (HPLC))

View Full Technical Monograph